Table 2 Systematic and ocular adverse events
From: Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
Sirolimus | Anti-VEGF | |
|---|---|---|
Systemic events | ||
Serious adverse events | 3a | 1b |
Minor adverse events | 3 | 8 |
Ocular events | ||
Serious adverse events | 3 | 0 |
Minor adverse events | 7 | 7 |